Coronavirus in India: Covaxin phase 3 trial data shows 77.8% efficacy to reduce symptomatic COVID-19 cases
Covaxin has not been granted permission to be used without restriction, even as Bharat Biotech had sought complete authorisation. Covaxin efficacy: Data from the phase 3 trials of Bharat Biotech’s Covaxin – India’s only indigenous coronavirus vaccine so far – has been shared by the manufacturer, and it shows that symptomatic COVID-19 cases can be … Read more